Cargando…

Clinical Characteristics and Healthcare Resource Utilization for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review

Background: Mucopolysaccharidosis II (MPS II; Hunter syndrome) is a rare, X-linked, life-limiting lysosomal storage disease characterized by a deficiency in the activity of the enzyme iduronate-2-sulfatase. Accumulation of glycosaminoglycans in tissues and organs throughout the body causes cellular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayodele, Olulade, Müller, Kersten, Setayeshgar, Solmaz, Alexanderian, David, Yee, Karen S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2022
Materias:	Hereditary Genetic Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098230/ https://www.ncbi.nlm.nih.gov/pubmed/35620452 http://dx.doi.org/10.36469/jheor.2022.33801

Ejemplares similares

Estimation of Health State Utility Values in Fabry Disease Using Vignette Development and Valuation
por: Hughes, Derralynn, et al.
Publicado: (2023)

Impact of the Timing of Enzyme Replacement Therapy Initiation and Cognitive Impairment Status on Outcomes for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review
por: Yee, Karen S., et al.
Publicado: (2022)

Quality of Life with Late-Onset Pompe Disease: Qualitative Interviews and General Public Utility Estimation in the United Kingdom
por: Hubig, Lena, et al.
Publicado: (2023)

Hereditary angioedema patients would prefer newer-generation oral prophylaxis
por: Geba, Daniela, et al.
Publicado: (2021)

Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey
por: El-Damanawi, Ragada, et al.
Publicado: (2017)

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
por: Rodriguez, Eva, et al.
Publicado: (2017)

Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017)

Inhibition of iduronic acid biosynthesis by ebselen reduces glycosaminoglycan accumulation in mucopolysaccharidosis type I fibroblasts
por: Maccarana, Marco, et al.
Publicado: (2021)

Immunological evaluation of patients with mucopolysaccharidosis (MPS)
por: Aranda, Carolina, et al.
Publicado: (2015)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2014)

Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study
por: Muenzer, Joseph, et al.
Publicado: (2023)

Phenotypic and genetic characteristics of 130 patients with mucopolysaccharidosis type II: A single-center retrospective study in China
por: Zhang, Zhenjie, et al.
Publicado: (2023)

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020)

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
por: Horgan, Claire, et al.
Publicado: (2022)

Differences in MPS I and MPS II Disease Manifestations
por: Hampe, Christiane S., et al.
Publicado: (2021)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Cervical spondylolisthesis in mucopolysaccharidosis type II
por: Rossi, Alessandro, et al.
Publicado: (2022)

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

Mucopolysaccharidosis Type VI with Recurrent Chest Infection
por: Numan, Ashraf, et al.
Publicado: (2023)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Biomarkers in patients with mucopolysaccharidosis type II and IV
por: Fujitsuka, Honoka, et al.
Publicado: (2019)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Parents’ experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS)
por: Somanadhan, S., et al.
Publicado: (2016)

Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I)
por: Barbosa Mendes, Ana, et al.
Publicado: (2019)

Mucopolysaccharidosis (MPS): Review of the literature and case series of five pediatric dental patients
por: Hirst, Lorna, et al.
Publicado: (2021)

Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
por: Muschol, Nicole M., et al.
Publicado: (2019)

Hurler Syndrome (Mucopolysaccharidosis Type 1): A Case Report
por: Khalid, Noman, et al.
Publicado: (2023)

Oxidative stress assessment by glutathione peroxidase activity and glutathione levels in response to selenium supplementation in patients with Mucopolysaccharidosis I, II and VI
por: de Oliveira-Silva, José Araújo, et al.
Publicado: (2019)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

Clinical Presentation of Mucopolysaccharidosis Type II (Hunter's Syndrome)
por: Chinawa, JM, et al.
Publicado: (2012)

Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
por: Burton, Barbara K., et al.
Publicado: (2020)

Mucopolysaccharidosis Type II: A Kenyan Case Series
por: Mungai, L. N. Wainaina, et al.
Publicado: (2021)

Clinical and Molecular Characterization of ALG1-CDG
por: Dhamija, Radhika, et al.
Publicado: (2016)

The Genetics of Febrile Seizures
por: Ram, Dipak, et al.
Publicado: (2015)

Incidental Findings: The Importance of Pretest Counseling
por: Buchtel, Kathryn M., et al.
Publicado: (2015)

Epileptic Encephalopathy Due to BRAT1 Pathogenic Variants
por: Srivastava, Siddharth, et al.
Publicado: (2016)

Ocular Manifestation of CACNA1A Pathogenic Variants
por: Reinson, Karit, et al.
Publicado: (2016)

Neurocognitive Functions and Behavior in Joubert Syndrome
por: Poretti, Andrea, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fo4ffq6e5grg1444ok8fq8rlc2